Research Facility 31 — Pflugerville, Texas

Research Facility 31 is a clinical research site located in Pflugerville, Texas, United States 78660.

Crixeo Clinical Trials Trust Score: 9/100 (FAILING). This profile has not yet been claimed by the site owner.

Research Facility 31 has participated in 1 clinical trials.

Therapeutic areas: Atopic Dermatitis.

Sponsors: Mylan Inc..

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Pflugerville

Browse all research sites in Texas · View every site in Pflugerville

• Austin Institute for Clinical Research
• Galderma Investigational Site
• Novartis Investigative Site
• Austin Institute For Clinical Research Aicr Pflugerville
• Study Site 359
• Pflugerville Dermatology Clinical Research Center
• Arcutis Biotherapeutics Clinical Site 26
• ARC Clinical Research at Kelly Lane
• Discovery Clinical Trials
• Vanda Investigational Site
• Austin Inst for Clinical Research
• Austin Institute for Clinical Research - Pflugerville

Sponsor Feasibility Report

Trust Score: 9/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Research Facility 31?

Research Facility 31 has a Crixeo Trust Score of 9/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Research Facility 31 conducted?

Research Facility 31 has 1 clinical trials on record. Their work covers Atopic Dermatitis.

Is Research Facility 31 accredited by Crixeo Clinical Trials?

Research Facility 31 has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Research Facility 31?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.